Tenon Medical Business Summary

Tenon Medical, Inc. (TNON) is a commercial-stage medical device company that generates revenue through the sale of proprietary surgical systems designed to treat sacroiliac (SI) joint disorders. Its primary business segments are centered on three clinical applications: primary SI joint fusion, revision procedures for failed implants, and augmenting thoracolumbar spinal fusions. The company’s core product, the Catamaran SI-Joint Fusion System, utilizes a unique posterior-lateral approach with a single titanium implant, while its 2025 acquisition of SiVantage assets added the SImmetry and SImmetry+ lateral fusion systems to its portfolio. Tenon competes directly with market leader SI-BONE, Inc., as well as TELA Bio, Inc. and Titan Medical Inc. Relative to these peers, Tenon positions itself as a specialized, multi-approach innovator, leveraging its dual-platform strategy to capture market share from traditional lateral-only competitors by offering more customizable treatment options for complex sacro-pelvic pathologies. Tenon was founded by Richard Ferrari and Richard Ginn, both of whom remain central to the leadership team. Steven M. Foster serves as President and CEO, bringing over 30 years of medical device experience from roles at NuVasive and ATEC Spine. Richard Ginn, the Chief Technology Officer, is a prolific inventor with over 300 patents and previously founded TransAortic Medical. Executive Chairman Richard Ferrari is a seasoned venture capitalist and Managing Director of Denovo Ventures, known for raising over $1 billion in capital and leading PQ Bypass to its acquisition by Endologix. The company’s board is further bolstered by Dr. Stephen H. Hochschuler, co-founder of the Texas Back Institute. Notable investors include Zuhlke Ventures AG, which holds a significant 28% stake, alongside institutional backing from Geode Capital Management and Renaissance Technologies.